The Value of RT-CGM to Support Achieving and Maintaining Glycemic Goals

This webinar was recorded on November 7, 2023
Sponsored by Dexcom

Therapeutic inertia is a major obstacle to effective diabetes management. Delaying intensification by one year in type 2 diabetes was associated with substantial clinical and economic burden.¹ The American Diabetes Association identifies the use of technology as one way to overcome therapeutic inertia, including the use of continuous glucose monitoring.²  

Join our webinar to understand the ways to utilize real-time continuous glucose monitoring (RT-CGM) and overcome barriers for improved glycemic outcomes that may help social determinants of health inequities. We will review the current standards of care and the beneficial evidence of RT-CGM early at diagnosis and when not meeting quality metrics.³ You can also learn how Dexcom Clarity is a useful tool to enable the health care team to monitor glucose information earlier to identify the optimal diabetes care plan.  

Speaker: 

Zakia Woods McManus, PharmD, CDCES 
Quality Coordinator/Ambulatory Care/Population Health Pharmacist 
Riverside Health System, Newport News, VA 

1. Ali SN et al. Adv Ther 2020 Feb;37(2)869–882. doi: 10.1007/s12325-019-01199-8.  

2. American Diabetes Association Practice Improvement Resources: https://therapeuticinertia.diabetes.org/practice-improvement-resources, accessed January 21,2022. 

3. American Diabetes Association. Diabetes Care. 2022;45(Suppl1):S97-S112. 

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenter are those of the sponsor or presenter and not of AMCP.  

Sponsored by: